NCT06880523

STRIDE (Durvalumab + Tremelimumab) With Lenvatinib vs STRIDE Alone in Unresectable Hepatocellular Carcinoma

A Phase II Study of STRIDE (Durvalumab + Tremelimumab) With Lenvatinib Versus STRIDE Alone in Patients With Unresectable Hepatocellular Carcinoma (SLIDE-HCC)

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 140 (estimated)
• Sponsor: Canadian Cancer Trials Group · Network
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to compare the effects on participants' and liver cancer by adding a drug that is used on its own to treat this disease to a combination of two other drugs which is also used to treat liver cancer, compared to the two-drug combination alone.

Detailed description

An earlier clinical trial showed that a single drug treatment for liver cancer helped stabilize or shrink participants' liver cancer and extend the time before their cancer got worse. A different clinical trial showed that a different two-drug combination helped extend how long participants with liver cancer lived after starting the treatment. Combinations of drugs that are similar to these treatments have been studied in a few people and seem promising, but it is not clear if the combination of all three drugs being used in this study can offer better results than standard treatment.

Conditions

• Hepatocellular Carcinoma

Interventions

Type	Name	Description
DRUG	STRIDE (durvalumab + tremelimumab)	As first treatment
DRUG	Durvalumab	monotherapy every 4 weeks
DRUG	Lenvatinib	Daily

Timeline

• Start date: 2025-10-21
• Primary completion: 2028-01-31
• Completion: 2028-12-31
• First posted: 2025-03-17
• Last updated: 2026-04-14

Locations

11 sites across 1 country: Canada